Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Antihypertensive drug treatment and susceptibility to SARS-CoV-2 infection in human PSC-derived cardiomyocytes and primary endothelial cells

ABSTRACT: Antihypertensive drug treatment and susceptibility to SARS-CoV-2 infection in human PSC-derived cardiomyocytes and primary endothelial cells

PROVIDER: PRJNA691950 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Antihypertensive drug treatment and susceptibility to SARS-CoV-2 infection in human PSC-derived cardiomyocytes and primary endothelial cells

Project description:hPSC-derived cadiomyocytes and primary endothelial cells were treated with lisinopril or losartan to assess whether antihypertensive drugs could impact SARS-CoV-2 entry in vitro

2021-08-26 | GSE164784 | GEO

Antihypertensive drug treatment and susceptibility to SARS-CoV-2 infection in human PSC-derived cardiomyocytes and primary endothelial cells.

Project description: Not available

| S-EPMC8407952 | biostudies-literature

Neonatal Transplantation Confers Maturation of PSC-Derived Cardiomyocytes Conducive to Modeling Cardiomyopathy

Project description:Pluripotent stem cell-derived cardiomyocytes (PSC-CMs) were transplanted into rats for one month to determine the change in morphology, structure, and function. Single cell RNA seq analysis was performed to compared the transcriptome of in vivo matured PSC-CMs to adult rat cardiomyocytes and in vitro cultured PSC-CMs.

2016-12-13 | GSE92247 | GEO

Neonatal Transplantation Confers Maturation of PSC-Derived Cardiomyocytes Conducive to Modeling Cardiomyopathy

Project description:Neonatal Transplantation Confers Maturation of PSC-Derived Cardiomyocytes Conducive to Modeling Cardiomyopathy

| PRJNA357025 | ENA

RNA-Seq of Human iPSC-cardiomyocytes infected with SARS-CoV-2

Project description:Coronavirus disease 2019 (COVID-19) is a viral pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 is predominantly defined by respiratory symptoms, but cardiac complications including arrhythmias, heart failure, and viral myocarditis are also prevalent. Although the systemic ischemic and inflammatory responses caused by COVID-19 can detrimentally affect cardiac function, the direct impact of SARS-CoV-2 infection on human cardiomyocytes is not well understood.

2020-06-19 | GSE150392 | GEO

SARS-CoV-2 infects human pluripotent stem cell-derived cardiomyocytes, impairing electrical and mechanical function

Project description:RNA-sequencing used to investigate the transcriptome response to Sars-cov-2 in ESC differentiated female cardiomyocytes and iPSC differentated male cardiomyctes

2021-03-09 | GSE162736 | GEO

Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR)

Project description:Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR)

| PRJNA215007 | ENA

Cardiomyocytes Infected by SARS-CoV-2 Recruit Cardiotoxic Macrophages

Project description:Cardiomyocytes Infected by SARS-CoV-2 Recruit Cardiotoxic Macrophages

| PRJNA637572 | ENA

PSC-IBD mucosal biology

Project description:Comparative colonic mucosal transcriptomics of 10 patients with PSC-IBD, 10 UC and 10 Healthy controls

2019-09-01 | E-MTAB-7915 | biostudies-arrayexpress

Transcriptomic response in the heart and kidney to different types of antihypertensive drug administration

Project description:To unravel antihypertensive drug-induced gene expression changes that are potentially related to the amelioration of end-organ damages, we performed in vivo phenotypic evaluation and transcriptomic analysis on the heart and the kidney, with administration of antihypertensive drugs to two inbred strains of (i.e., hypertensive and normotensive) rats. We chose to use six antihypertensive classes: enalapril (angiotensin converting enzyme inhibitor), candesartan (angiotensin receptor blocker), hydrochlorothiazide (diuretics), amlodipine (calcium-channel blocker), carvedilol (vasodilating -blocker) and hydralazine. In the tested rat strains, four of six drugs, including two renin-angiotensin system (RAS) inhibitors, were effective for BP lowering, whereas the remaining two drugs were not. Besides BP lowering, there appeared to be some inter-drug heterogeneity in phenotypic changes, such as suppressed body weight (Bw) gain and Bw-adjusted heart weight reduction. For the transcriptomic response, a considerable number of genes showed prominent mRNA expression changes either in a BP-dependent or BP-independent manner with substantial diversity between the target organs. Noticeable changes of mRNA expression were induced particularly by RAS blockade, e.g., for genes in the natriuretic peptide system (Nppb and Corin) in the heart and for those in the RAS/ kallikrein-kinin system (Ren and rat Klk1 paralogs) and those related to calcium ion binding (Calb1 and Slc8a1) in the kidney. The heart data comprises of this submission and part of E-MTAB-9244.

2022-04-15 | E-MTAB-10667 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data